ReviewCurrent rheumatology reports2019
Advances Toward Precision Medicine in Juvenile Dermatomyositis.
Review in Current rheumatology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrated multi-dimensional analyses reveal a BTN3A2-centered diagnostic risk score and a monocyte-T cell axis as central drivers of dermatomyositis.Clinical rheumatology · 2026Article
- Imbalance of peripheral blood Th17/Treg increases neutrophil-to-lymphocyte ratio in patients with dermatomyositis.American journal of translational research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewWe seek to provide a summary of the recent advances in juvenile dermatomyositis (JDM) that are moving the field toward precision care and personalized medicine for this uncommon condition. RECENT
findingsThere has been a recent international focus on developing uniform classification, disease monitoring, and treatment for juvenile dermatomyositis. In addition, there has been a steady development of translational studies to determine the genetic determinants, transcriptomic profiles, and immune cell phenotypes in JDM. Recent work toward standardization of disease classification, monitoring, and assessments together with advances in science, technology, and computing will facilitate the advancement toward true precision and personalized medicine in juvenile dermatomyositis in the near future.
Indexed as
Identifiers
31813083What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.